ストックスクリーナーアプリを入手
0.2301
1.96%
-0.0046
前日終値:
$0.2347
開ける：
$0.235
24時間の取引高:
734.74K
Relative Volume:
0.34
時価総額：
$20.76M
収益：
-
当期純損益:
$-166.14M
株価収益率:
-0.1198
EPS:
-1.92
ネットキャッシュフロー:
$-139.92M
1週間 パフォーマンス:
-7.89%
1か月 パフォーマンス:
-18.06%
6か月 パフォーマンス:
-63.83%
1年 パフォーマンス:
-81.74%
1日の値動き範囲:
$0.2239
$0.2401
1週間の範囲:
$0.2239
$0.2541
52週間の値動き範囲:
$0.2239
$1.555
Allakos Inc Stock (ALLK) Company Profile
ALLK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
0.2301 | 20.76M | 0 | -166.14M | -139.92M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-17 | ダウングレード | Jefferies | Buy → Hold |
| 2024-01-16 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-18 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-08 | 再開されました | Jefferies | Buy |
| 2023-09-27 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-05-12 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-07 | 開始されました | Piper Sandler | Overweight |
| 2022-09-12 | ダウングレード | SMBC Nikko | Neutral → Underperform |
| 2021-12-22 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-22 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-12-22 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-12-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-07-15 | 開始されました | Cowen | Outperform |
| 2021-05-18 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-15 | 開始されました | BofA Securities | Buy |
| 2020-12-21 | 開始されました | SVB Leerink | Outperform |
| 2020-02-27 | 開始されました | Barclays | Underweight |
| 2020-02-04 | 再開されました | Goldman | Neutral |
| 2018-08-13 | 開始されました | Goldman | Neutral |
| 2018-08-13 | 開始されました | Jefferies | Buy |
| 2018-08-13 | 開始されました | William Blair | Outperform |
すべてを表示
Allakos Inc (ALLK) 最新ニュース
Allakos stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Allakos stock plunges to 52-week low of $0.23 amid market challenges - Investing.com India
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - Defense World
Analyzing Allakos (NASDAQ:ALLK) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) - Defense World
Allakos Inc.: Hold Rating Amid Restructuring and Financial Uncertainty - TipRanks
Allakos faces potential Nasdaq delisting over share price By Investing.com - Investing.com Australia
Allakos Reports Q4 2024 Results Amid Strategic Shift - TipRanks
Allakos faces potential Nasdaq delisting over share price - Investing.com India
Allakos Inc. (ALLK) reports earnings - Quartz
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results - The Manila Times
Allakos Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Allakos Swings to Surprise Q4 Profit as Major Restructuring Takes Shape - StockTitan
Allakos (ALLK) Projected to Post Quarterly Earnings on Thursday - Defense World
The Curious Case of Allakos - substack.com
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 3 DAY APPLICATION DEADLINE ALERT - ACCESS Newswire
Allakos Inc. (ALLK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Lee joins Lycia as CMO - BioCentury
It is Poised to be a Bull Market for Allakos Inc (ALLK) - SETE News
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - EIN News
Introducing Our Rant Against Allakos Inc - US Post News
FY2024 EPS Estimates for Allakos Lowered by Leerink Partnrs - Defense World
Allakos Inc [ALLK] Officer makes an insider purchase of 21,116 shares worth 23219.0. - Knox Daily
This Week’s 14.26% Gain In Allakos Inc (NASDAQ: ALLK) Taught Us Something New - Marketing Sentinel
Evaluating Allakos: Strategic Review, NOL Potential, and Kevin Tang's Activist Stake Amidst Biopharma Challenges - Smartkarma
What To Expect From Eli Lilly’s (LLY) Q4 Earnings - The Globe and Mail
Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR
Such Is The Power Of Allakos Inc (NASDAQ: ALLK) - Stocks Register
Allakos Inc: -85.21% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Allakos Inc - GuruFocus.com
Allakos stock tanks after company announces mass layoffs - MSN
The time has not yet come to remove your chips from the table: Allakos Inc (ALLK) - SETE News
Allakos stock plunges to 52-week low of $0.23 amid steep annual decline - Investing.com
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga India
Allakos stock tumbles following AK006 trial discontinuation - MSN
Bay Area biotech firm guts staff, shuts trial after dangerous side effects - SFGATE
Allakos plunges 75% on phase 1 data for urticaria asset - MSN
Allakos (NASDAQ:ALLK) Cut to Hold at Piper Sandler - Defense World
Allakos (NASDAQ:ALLK) Cut to Hold at Citizens Jmp - Defense World
Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade - MSN
BioAge drops obesity drug; Akero, 89bio cash in on MASH data - BioPharma Dive
Allakos to cease AK006 development after trial setback - MSN
Allakos cuts 75% of workforce after chronic hives trial failure - Clinical Trials Arena
Bay Area biotech firm Allakos suddenly on brink of collapse after trial flops - MSN
Allakos stock hits 52-week low at $0.3 amid market challenges - Investing.com Canada
Allakos shares fall as Jefferies cuts price target to $0.40 By Investing.com - Investing.com Nigeria
Allakos decimated as Phase I Trial of AK006 fails - The Pharma Letter
Allakos shares fall as Jefferies cuts price target to $0.40 - MSN
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Benzinga India
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds - The Business Journals
Allakos Inc (ALLK) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):